+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Immuno-oncology Clinical Trials Market Research Report by Design, Phase, Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 142 Pages
  • January 2023
  • Region: United States
  • 360iResearch™
  • ID: 5722270
The United States Immuno-oncology Clinical Trials Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Immuno-oncology Clinical Trials Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Immuno-oncology Clinical Trials Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Immuno-oncology Clinical Trials Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Immuno-oncology Clinical Trials Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Immuno-oncology Clinical Trials Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Immuno-oncology Clinical Trials Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Design, the market is studied across Expanded Access Trials, Interventional Trials, and Observational Trials.
  • Based on Phase, the market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Indication, the market is studied across Hematological Cancer and Solid Tumors.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Immuno-oncology Clinical Trials Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Immuno-oncology Clinical Trials Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Immuno-oncology Clinical Trials Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Immuno-oncology Clinical Trials Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Immuno-oncology Clinical Trials Market, including AstraZeneca PLC, BioNTech SE, Bristol Myers Squibb Company, Exscientia PLC, F. Hoffmann-La Roche Ltd., ICON PLC, IO Biotech ApS, IQVIA Inc., Laboratory Corporation of America Holdings, Medpace, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Rubius Therapeutics, Inc., and Syneos Health, Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Immuno-oncology Clinical Trials Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Immuno-oncology Clinical Trials Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Immuno-oncology Clinical Trials Market?
4. What is the competitive strategic window for opportunities in the United States Immuno-oncology Clinical Trials Market?
5. What are the technology trends and regulatory frameworks in the United States Immuno-oncology Clinical Trials Market?
6. What is the market share of the leading vendors in the United States Immuno-oncology Clinical Trials Market?
7. What modes and strategic moves are considered suitable for entering the United States Immuno-oncology Clinical Trials Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for personalized medicine-based novel treatments
5.1.1.2. Rising adoption of advanced omics technologies for biomarker discovery
5.1.2. Restraints
5.1.2.1. Limited scientific data and staffing constraints
5.1.3. Opportunities
5.1.3.1. New developments in the research field of immuno-oncology
5.1.3.2. Transformation of novel and innovative immunotherapy laboratory services
5.1.4. Challenges
5.1.4.1. Dearth of clinical study designs
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Immuno-oncology Clinical Trials Market, by Design
6.1. Introduction
6.2. Expanded Access Trials
6.3. Interventional Trials
6.4. Observational Trials

7. Immuno-oncology Clinical Trials Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV

8. Immuno-oncology Clinical Trials Market, by Indication
8.1. Introduction
8.2. Hematological Cancer
8.3. Solid Tumors

9. California Immuno-oncology Clinical Trials Market
9.1. Introduction

10. Florida Immuno-oncology Clinical Trials Market
10.1. Introduction

11. Illinois Immuno-oncology Clinical Trials Market
11.1. Introduction

12. New York Immuno-oncology Clinical Trials Market
12.1. Introduction

13. Ohio Immuno-oncology Clinical Trials Market
13.1. Introduction

14. Pennsylvania Immuno-oncology Clinical Trials Market
14.1. Introduction

15. Texas Immuno-oncology Clinical Trials Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Product Portfolio Analysis, By Key Player
16.5. Competitive Scenario
16.5.1. Merger & Acquisition
16.5.2. Agreement, Collaboration, & Partnership
16.5.3. New Product Launch & Enhancement
16.5.4. Investment & Funding
16.5.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. AstraZeneca PLC
17.2. BioNTech SE
17.3. Bristol Myers Squibb Company
17.4. Exscientia PLC
17.5. F. Hoffmann-La Roche Ltd.
17.6. ICON PLC
17.7. IO Biotech ApS
17.8. IQVIA Inc.
17.9. Laboratory Corporation of America Holdings
17.10. Medpace, Inc.
17.11. Merck KGaA
17.12. Novartis AG
17.13. Pfizer Inc.
17.14. Rubius Therapeutics, Inc.
17.15. Syneos Health, Inc.

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET DYNAMICS
FIGURE 8. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY DESIGN, 2030
FIGURE 12. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS TRIALS, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL TRIALS, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL TRIALS, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY PHASE, 2030
FIGURE 18. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
FIGURE 20. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
FIGURE 21. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 23. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 25. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
FIGURE 26. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
FIGURE 27. CALIFORNIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. FLORIDA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 29. ILLINOIS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 30. NEW YORK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. OHIO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 32. PENNSYLVANIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 33. TEXAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 34. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 35. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 36. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS TRIALS, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS TRIALS, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL TRIALS, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL TRIALS, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL TRIALS, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL TRIALS, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY STATE, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY STATE, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY STATE, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL CANCER, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL CANCER, BY STATE, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. CALIFORNIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 27. CALIFORNIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 28. CALIFORNIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 29. CALIFORNIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 30. FLORIDA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 31. FLORIDA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 32. FLORIDA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 33. FLORIDA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. ILLINOIS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 35. ILLINOIS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 36. ILLINOIS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 37. ILLINOIS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. NEW YORK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 39. NEW YORK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 40. NEW YORK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 41. NEW YORK IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. OHIO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. OHIO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 44. OHIO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 45. OHIO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. PENNSYLVANIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 47. PENNSYLVANIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 48. PENNSYLVANIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 49. PENNSYLVANIA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. TEXAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 51. TEXAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DESIGN, 2018-2030 (USD MILLION)
TABLE 52. TEXAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
TABLE 53. TEXAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 55. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 56. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 57. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 58. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 59. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 60. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET MERGER & ACQUISITION
TABLE 61. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 62. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 63. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET INVESTMENT & FUNDING
TABLE 64. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 65. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: LICENSE & PRICING

Companies Mentioned

  • AstraZeneca PLC
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Exscientia PLC
  • F. Hoffmann-La Roche Ltd.
  • ICON PLC
  • IO Biotech ApS
  • IQVIA Inc.
  • Laboratory Corporation of America Holdings
  • Medpace, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Rubius Therapeutics, Inc.
  • Syneos Health, Inc.

Methodology

Loading
LOADING...